Despite significant advances, the optimal nutritional management of low birth weight infants remains controversial, particularly as it relates to protein/nitrogen requirements. This is because of lack of a consensus regarding (a) the anticipated rate of growth and (b) the heterogeneity of the population, specifically as evaluated by gestational age. Even though it has been suggested that postnatal growth of prematurely born infants should approach the rate of growth for a normal fetus, assuming it to be the best surrogate for extrauterine growth, it still remains to be demonstrated that such a goal can be achieved in contemporary clinical practice. Recent reports of large collaborative studies have demonstrated that in extremely low birth weight infants extrauterine growth curves depart significantly from the intrauterine growth curve. This discrepancy is accentuated in the more premature neonate (born at less than 27 weeks' gestation), where extrauterine growth curves depart the farthest from the intrauterine growth curve.
INTRACELLULAR PROTEIN SYNTHESIS AND BREAKDOWN
To understand the dynamic aspects of cellular protein metabolism, not only do the multiple processes involved in the synthesis and degradation of a specific protein need to be evaluated, but also those factors that determine the activation and inactivation of a functional protein must be considered. The developmental regulation of these mechanisms and their role in the fetal and neonatal growth have not been examined. In recent years major advances in our understanding of intracellular proteolysis have pointed to the important role of ubiquitin-dependent protein degradation system in cell cycle regulation, receptor function, control of growth, development, and response to stress such as seen in sepsis, cancer cachexia, diabetes, denervation atrophy, etc. 3 -5 Recent studies have demonstrated that the bulk of intracellular protein is degraded by the ubiquitinproteosome pathway. 6 The other two pathways of protein degradation, A large number of studies in recent years have described protein and nitrogen metabolism in the neonate. However, the majority of these data are difficult to interpret because of a number of confounding variables, particularly in very low birth weight ( VLBW ) infants. In contrast, application of state -of -the -art tracer isotopic and molecular biology methods in isolated cell system and whole animals has resulted in major advances in our understanding of the regulation of protein breakdown, synthesis, and protein accretion. The following workshop summary reviews the recent developments in basic physiology of protein metabolism in cellular and animal models in relation to human preterm infants, and identifies the important areas toward which future basic and clinical research should be directed to provide for optimal nitrogen accretion and growth of the VLBW infant. Journal of Perinatology 2001; 21:320 -323.
State of the Art
i.e., lysosomes, mitochondrial proteases, and other cytosolic protease, make a smaller contribution. Protein substrates targeted for degradation by the ubiquitin proteosome pathway are initially marked by the covalent attachment of a protein cofactor ubiquitin to a side-chain lysine (ubiquitination) on the target protein. The ubiquitin-conjugation reactions are repeated, forming a chain of five or more ubiquitin linked to each other and then to protein substrate. This modification of the substrate protein leads to a rapid degradation by a large proteolytic complex, the 26S proteosome, which requires ATP to function. 3 The ubiquitination of protein is ATP-dependent and regulated by a number of hormones and cytokines. The ubiquitin-proteosome system is involved in the degradation of abnormal proteins such as mutant and damaged proteins, short-lived normal proteins, regulatory proteins, enzymes, long-lived normal proteins such as skeletal muscle contractile protein, and a host of other proteins. Although the ubiquitinproteosome system is expressed in every cell and tissue, its role in the growth, development, cellular proliferation and differentiation of the fetus and neonate, and in specific tissues, remains to be elucidated.
As with proteolysis, protein synthesis also involves a series of complex processes that translate information encoded in mRNA into protein. These include (1) initiation, the step at which the initiator methionyl-tRNA (met-tRNA i ) are bound to the 40S and 60S ribosomal subunits to form a translationally competent ribosome; (2) elongation, where amino acids are incorporated into a growing peptide chain; and (3) termination, the step at which the completed peptide chain is released from the ribosome. Each of these processes are modulated by a group of proteins known as eukaryotic initiation factors (eIFs), elongation factors (eEFs) and releasing factors (RFs). Although translation can be regulated at any of these steps, in most instances the initiation step is considered rate controlling. 7 -9 In the skeletal muscle, the initiation is controlled by a complex interplay between growth promoting hormones such as insulin, insulin-like growth factors, and counterregulatory hormones such as glucagon, glucocorticoids, etc. In addition, amino acids, in particular the branched-chain amino acid leucine, have a stimulatory effect on initiation above and beyond their role as substrates for protein synthesis. Davis et al. 10 and Kimball et al. 11 have recently examined developmental changes in the regulation of translational initiation in the skeletal muscle of growing pigs. Feeding stimulated protein synthesis in both 7-and 26-day pigs, although the magnitude of increase was much greater in the younger pigs than the older pigs. This increase was associated with a stimulation of the mRNA, but not the met-tRNA i binding step in initiation, and an increased phosphorylation of kinase in the insulin and IGF-1 signal transduction pathways. The increase was greater in younger animals. These data suggest a developmental or age-related regulation of protein synthesis in growing animals. It remains to be determined whether the low birth weight premature infant also has a similar ribosomal apparatus or the capacity to respond to growth stimuli. In addition, the impact of change in the energy state and various nutrients and growth factors on the regulation of protein synthesis has not been explored. Other factors that contribute to the ultimate regulation of protein synthesis include cellular amino acid transporters that, by themselves, are regulated by the availability of amino acids. Omission of amino acids from the cell culture medium has been shown to lead to a substantial decrease in protein synthesis. 12 At the same time, amino acid depletion initiates molecular events that lead to increased expression of genes that encode protein synthesis. 13 Finally, intracellular protein synthesis is further regulated by the intracellular compartmentation of certain enzymes such as transaminases that regulate the transfer and interorgan shuttling of nitrogen, e.g., from periphery to liver. 14 
STUDIES IN WHOLE ANIMALS
Animal models such as the sheep fetus and the newborn pig have allowed investigators to systemically evaluate protein and amino acid metabolism in vivo. These data show that the fetal amino acid metabolism is characterized by a large rate of placental transport and uptake by the fetus, high rate of protein synthesis, and accretion accompanied by high rates of oxidation of glucose and amino acids and urea production by the fetus. 15, 16 In addition, certain amino acids have unique metabolic characteristics, e.g., glutamine is an important source of glutamate, which serves as an oxidative substrate for placenta; serine is not transported across ovine placenta; however, it is released by the placenta in fetal circulation where it is taken up by the liver and converted to glycine. 17 The latter thus serves as the precursor for placental production of serine. Serine, as the major source of onecarbon unit, together with folate plays an important role in methylation of homocysteine to methionine. How the metabolism of these amino acids is related to development and prevention of neural tube defects in humans remains unknown. The relation between these amino acid cycles and fetal well-being has not been well studied, particularly in human pregnancy, and the transition from fetal to neonatal amino acid metabolism remains to be evaluated. The newborn pig, because of its rapid rate of growth and metabolic characteristics somewhat similar to humans, has been extensively used for nutritional studies. Studies by Wykes et al, 18 House et al., 19 and Roberts et al. 20 have determined phenylalanine and tyrosine requirements in the newborn pig, and have shown that phenylalanine is not a suitable source of tyrosine. Using this model, they have estimated the daily requirement of several essential and nonessential amino acids during the period of rapid neonatal growth. 21 -23 Studies by Stoll et al. 24, 26 and Reeds et al., 25 in the neonatal pig, have demonstrated the crucial role of amino acids in several aspects of intestinal function and the role of the gut in whole body amino acid metabolism. Using isotopic tracer methods, these investigators have demonstrated that nutritionally significant quantities of dietary amino acids are utilized in first pass by the splanchnic tissue, and that intestinal tissue account for as much as 70% of the total splanchnic amino acid metabolism. 24, 26 Intestinal protein synthesis appears to be the dominant pathway for the splanchnic utilization of essential amino acids and can account for 35% to 50% of the whole body utilization of essential amino acids. Additionally, amino acids, in particular glutamate and aspartate, are important oxidative substrates for the gut. Other amino acids whose metabolism is closely related to the intestine include arginine and glutamine. In this context, little information on splanchnic amino acid metabolism in the human neonate is available, both in term gestation and for those born prematurely. Because glutamine is also an important substrate for gut metabolism, few studies have examined the metabolism of gut in human neonate. 27 Addition of glutamine as nutritional supplement in VLBW infants has resulted in rather inconclusive results. 28 -31 This is in contrast to studies in adults where significant advantages are evident, particularly in catabolic state such as following bone marrow transplant, trauma, and sepsis. 31 -33 
STUDIES IN HUMAN
Stable isotopic tracer methods have allowed investigators to examine the transport of several essential and nonessential amino acids across the human placenta in vivo and to investigate various aspects of their metabolism in the neonate. 34 -37 Very few studies have qualified the dynamic aspects of protein/amino acid metabolism in the human newborn, in particular the very low birth eight infant. These data are confounded by the intercurrent illnesses and the need for life support interventions, including pharmacological agents, etc. 38 Using stable isotopic tracer methods, Hertz et al., 39 Denne et al., 40 and Poindexter et al. 41 have shown that the VLBW infants have high rates of proteolysis, which are not influenced by the administration of glucose or intravenous amino acids. 39 -41 Strategies to improve amino acid accretion by administering insulin or growth hormone have been largely unsuccessful. 42 -44 The lack of a definitive positive effect may, in part, be due to prematurity (ontogeny) or other confounding influences in the extremely preterm infant. In the growing low birth weight infant, Kashyap and colleagues 45, 46 have shown that the rate and composition of the weight gain can be predicted from the composition of their diet, and that the urinary nitrogen excretion is a continuous function of their protein-to-energy ratio of their dietary intake. These data and their derived mathematical models should help develop future dietary intervention strategies for the VLBW infants.
FUTURE RESEARCH
Even though major strides have been made in our understanding of protein/nitrogen metabolism in the human newborn and several intervention strategies have been developed, little information exists regarding the intracellular regulation of protein synthesis and breakdown during development. In addition, the signal(s) that regulate the change in fractional rate of protein synthesis in the fetus during development and the signaling mechanism(s) between placenta and fetal liver need to be identified. Although the goal of nutritional management of VLBW infants has been defined as that which would parallel intrauterine growth of the normal fetus, to what extent the nutritional requirement of the VLBW infant reflects continued fetal metabolism in contrast to metabolic adaptation to extrauterine environment should be determined. In this context, questions to be addressed include the definition of adequate or optimal rate of growth, optimal time to regain birth weight, role of growth factors such as insulin, nucleotides, etc., in nutritional support, the optimal quality and quantity of protein, and the role of supplemental nonessential amino acids such as glutamine.
Additional issues unique to the VLBW infant also require careful evaluation and consideration. These include the development of strategies for optimal nutritional support in the face of sepsis, polypharmacy and chronic lung disease; the supplement need for vitamins; and the deleterious effects of glucocorticoids used for the management of chronic lung disease. Consideration also needs to be given to define the best outcome measures . . . should it be the weight, growth velocity, head circumference, or other functional measures such as neurodevelopmental outcome, etc. Only when several of these questions are carefully addressed using modern technologies of isotopic tracers, body composition measurements, differential display of gene transcription, proteomics, and other molecular biology methods, combined with well-controlled neurodevelopmental followup studies, will it be possible to develop optimal strategies for the best possible nutritional/nitrogen support of the VLBW infant.
